To Lower Drug Prices, Look At Generic Industry Health Rather Than FDA, Woodcock Says
Executive Summary
US FDA can encourage and increase competition, but cannot force generic companies to enter markets deemed unprofitable, CDER director says.
You may also be interested in...
US FDA Changing View Of Citizen Petition Response Time, Could Eliminate Serial Refiling
By aligning petition filing deadlines with user fee goals, agency could discourage petitions that need response within 150 days, potentially ending non-substantive response practice.
US FDA Changing View Of Citizen Petition Response Time, Could Eliminate Serial Refiling
By aligning petition filing deadlines with user fee goals, agency could discourage petitions that need response within 150 days, potentially ending non-substantive response practice.
US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals
Agency will work past generic goal dates if approval can be achieved quickly thereafter, but now must create policy defining criteria for those situations.